- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 69-83 of
249 results
2139 Exhibit: Tohen et al, Am J Psychiatry
Document
IPR2020-01053, No. 2139-157 Exhibit - Tohen et al, Am J Psychiatry (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2079 Exhibit: Pareek, Factors Affecting Non Compliance to Psychotropic Drugs ofP...
Document
IPR2020-01053, No. 2079-129 Exhibit - Pareek, Factors Affecting Non Compliance to Psychotropic Drugs ofPatients with Psychosis as Perceived by their Family MembersAttending the Psychiat...
|
|
Cite Document
2071 Exhibit: O���Day et al, Long term cost effectiveness of atypical antipsychoticsi...
Document
IPR2020-01053, No. 2071-121 Exhibit - O���Day et al, Long term cost effectiveness of atypical antipsychoticsin the treatment of adults with schizophrenia in the US (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2044 Exhibit: Franklin, Lurasidone for the treatment of bipolar depression an evide...
Document
IPR2020-01053, No. 2044-93 Exhibit - Franklin, Lurasidone for the treatment of bipolar depression an evidence based review (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2048 Exhibit: Symbyax�� Label
Document
IPR2020-01053, No. 2048-97 Exhibit - Symbyax�� Label (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2051 Exhibit: Thase, Quetiapine monotherapy for bipolar depression
Document
IPR2020-01053, No. 2051-100 Exhibit - Thase, Quetiapine monotherapy for bipolar depression (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2046 Exhibit: Kane et al Clozapine for the Treatment Resistant Schizophrenia
Document
IPR2020-01053, No. 2046-95 Exhibit - Kane et al Clozapine for the Treatment Resistant Schizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2054 Exhibit: Sachs et al, Efficacy and Safety of Adjunctive Oral Ziprasidone forAc...
Document
IPR2020-01053, No. 2054-103 Exhibit - Sachs et al, Efficacy and Safety of Adjunctive Oral Ziprasidone forAcute Treatment of Depression in Patients With Bipolar I Disorder (P.T.A.B. Mar. 11, 20...
|
|
Cite Document
2091 Exhibit: Comparison of Atypical Antipsychotics
Document
IPR2020-01053, No. 2091-140 Exhibit - Comparison of Atypical Antipsychotics (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2086 Exhibit: Rajagopalan et al, Cost Utility Analysis of Lurasidone VersusAripipraz...
Document
IPR2020-01053, No. 2086-135 Exhibit - Rajagopalan et al, Cost Utility Analysis of Lurasidone VersusAripiprazole in Adults with Schizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2136 Exhibit: McElroy et al, Pharmacologic Agents for the Treatment of AcuteBipol...
Document
IPR2020-01053, No. 2136-154 Exhibit - McElroy et al, Pharmacologic Agents for the Treatment of AcuteBipolar Mania (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2072 Exhibit: Dainippon Sumitomo Pharma Co, Ltd, Supplementary Financial Dataf...
Document
IPR2020-01053, No. 2072-122 Exhibit - Dainippon Sumitomo Pharma Co, Ltd, Supplementary Financial Datafor Year Ended March 31, 2014 (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2087 Exhibit: Mattingly et al, Switching to Lurasidone Following 12 Months ofTreatm...
Document
IPR2020-01053, No. 2087-136 Exhibit - Mattingly et al, Switching to Lurasidone Following 12 Months ofTreatment with Risperidone (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2141 Exhibit: News Release FDA Approves Once Daily Latuda lurasidoneHCl for Tr...
Document
IPR2020-01053, No. 2141-159 Exhibit - News Release FDA Approves Once Daily Latuda lurasidoneHCl for Treatment of Patients with Schizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
2056 Exhibit: Stimmel at al, Ziprasidone An Atypical Antipsychotic Drug for theTrea...
Document
IPR2020-01053, No. 2056-105 Exhibit - Stimmel at al, Ziprasidone An Atypical Antipsychotic Drug for theTreatment of Schizophrenia (P.T.A.B. Mar. 11, 2021)
|
|
Cite Document
